Parsnip Extract Composition for Intestinal Health and Leaky Gut Treatment
Summary
USPTO published patent application US20260097089A1 for a composition containing parsnip extract as an active ingredient. The composition is designed to reduce tight junction protein downregulation, promote beneficial intestinal bacteria proliferation, maintain acidic intestinal environment, and reduce intestinal permeability. The application indicates the composition may be used in foods, feeds, pharmaceuticals, or quasi-drugs for improving intestinal health and preventing or treating leaky gut syndrome, obesity, or metabolic diseases.
What changed
USPTO published a patent application (US20260097089A1) for a composition containing parsnip extract as an active ingredient. The disclosed composition reduces tight junction protein downregulation, promotes beneficial intestinal bacteria, maintains a slightly acidic intestinal environment, and reduces intestinal permeability. The application also discloses effects on lipid metabolism-related factors including ACC, FAS, SREBP1, ChREBP, G6PD, and C/EBPalpha, as well as benefits for body fat reduction, blood sugar, insulin resistance, and liver damage markers.
Affected parties including food manufacturers, pharmaceutical companies, and dietary supplement makers should monitor this application to assess potential competitive implications or licensing opportunities. The broad claim scope covering foods, feeds, pharmaceuticals, and quasi-drugs suggests wide commercial applicability if the patent is granted. Inventors listed include Ho-Young Park, Ji Eun Park, Miri Park, Hee-Kyoung Son, Yu Ra Lee, Guijae Yoo, Sang-Yoon Choi, Yoon-sook Kim, Sang Keun Ha, and Donghwan Kim.
What to do next
- Monitor for patent grant status
- Review claims for freedom-to-operate analysis if developing similar products
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION FOR IMPROVING INTESTINAL HEALTH, OR PREVENTING, IMPROVING OR TREATING LEAKY GUT SYNDROME OR METABOLIC DISEASES CONTAINING PARSNIP EXTRACT AS AN ACTIVE INGREDIENT
Application US20260097089A1 Kind: A1 Apr 09, 2026
Inventors
Ho-Young PARK, Ji Eun Park, Miri Park, Hee-Kyoung Son, Yu Ra Lee, Guijae Yoo, Sang-Yoon Choi, Yoon-sook Kim, Sang Keun Ha, Donghwan Kim
Abstract
The present disclosure relates to a composition containing parsnip extract as an active ingredient which reduces the downregulation of tight junction protein expression, promote the proliferation of beneficial intestinal bacteria, improve the intestinal environment such as maintaining a slightly acidic intestinal environment, and have effects such as reducing intestinal permeability. Therefore, the composition may improve intestinal health and prevent, treat, or improve leaky gut syndrome, and may be used as a material for foods, feeds, pharmaceuticals, or quasi-drugs. Additionally, the composition may have body fat reduction and weight loss activities, reduce the protein expression of lipid metabolism-related factors such as ACC, FAS, SREBP1, ChREBP, G6PD, or C/EBPα, and have effects such as reducing liver weight, reducing blood sugar, reducing ALT or AST levels, reducing insulin resistance, and reducing extent of liver damage. Therefore, the composition may prevent, treat, or improve obesity or a metabolic disease.
CPC Classifications
A61K 36/23 A61P 1/00 A61P 1/16 A61P 3/04 A61P 3/06 A61P 3/10 A61K 2236/15 A61K 2236/17 A61K 2236/331
Filing Date
2025-10-01
Application No.
19347064
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.